Intended for healthcare professionals

Practice NIHR Alerts

Male sling is as good as more complex surgery for incontinence after prostate surgery

BMJ 2023; 381 doi: (Published 05 June 2023) Cite this as: BMJ 2023;381:p1179
  1. Helen Saul, editor in chief1,
  2. Brendan Deeney, science writer1,
  3. Samantha Cassidy, science writer1,
  4. Jemma Kwint, senior research fellow1 ,
  5. Lynda Constable, trial manager2,
  6. Paul Abrams, honorary professor of urology3
  1. 1NIHR Evidence, Twickenham, UK
  2. 2University of Aberdeen
  3. 3University of Bristol
  1. Correspondence to H Saul evidence{at}

The study

Constable L, Abrams P, Cooper D, et. Synthetic sling or artificial urinary sphincter for men with urodynamic stress incontinence after prostate surgery: the MASTER non-inferiority RCT. Health Technol Assess 2022;26:1-152

To read the full NIHR Alert, go to:


  • Competing interests: Paul Abrams reports consultancies with Astellas Pharma Inc (Tokyo, Japan), Ipsen (Paris, France) and Recordati (Milan, Italy); reports being a lecturer for Astellas Pharma Inc, Pfizer Inc (New York, NY, USA), Cipla (Mumbai, India), Ferring Pharmaceuticals (Saintt-Prex, Switzerland) and Sun Pharma (Mumbai, India); and is a triallist for Astellas Pharma Inc, outside the submitted work. Chris Harding reports personal fees from Astellas Pharma Inc, Medtronic (Dublin, Ireland) and Allergan (Dublin, Ireland); grants from Medtronic; personal fees from Teleflex Medical (Wayne, PA, USA) and GlaxoSmithKline (Brentford, UK); and research grants from the National Institute for Health and Care Research (NIHR) and The Urology Foundation (London, UK) outside the submitted work. Marcus J Drake reports personal fees from Astellas Pharma Inc and Pfizer Inc, outside the submitted work and is a trustee of the International Continence Society (Bristol, UK). Nikki Cotterill reports grants from NIHR during the conduct of the study. Craig Ramsay reports membership of the NIHR Health Technology Assessment (HTA) General Board (2017-present). John Norrie reports grants from the University of Aberdeen (Aberdeen, UK) and the University of Edinburgh (Edinburgh, UK) during the conduct of the study and declares membership of the following NIHR/Medical Research Council boards: Efficacy and Mechanism Evaluation (EME) Funding Board (chairperson, 2019-present), Cardiopulmonary Resuscitation Decision-making Committee (2016), HTA Commissioning Board (2010-16), HTA Commissioning Sub-Board (Expression of Interest) 2012-16, HTA Funding Boards Policy Group (2016), HTA General Board (2016-19), HTA Post-Board Funding Teleconference (2016-19), NIHR Clinical Trials Unit Standing Advisory Committee (2017-present), NIHR HTA and EME Editorial Board (2014-19) and Pre-exposure Prophylaxis Impact Review Panel (2017-present). All authors contributed to the development and review of this summary, as part of the wider NIHR Alerts editorial team.

  • More summaries of NIHR research are available at:

  • Disclaimer: NIHR Alerts are owned by the Department of Health and Social Care and are made available to The BMJ under licence. NIHR Alerts report and comment on health and social care research but do not offer any endorsement of the research. The NIHR assumes no responsibility or liability arising from any error or omission or from the use of any information contained in NIHR Alerts.

  • Permission to reuse these articles should be directed to

View Full Text

Log in

Log in through your institution


* For online subscription